SCHEMBL10256901

SCHEMBL10256901

C[N+]1(Cc2ccccc2)CCCCCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.61
CHRNA4 P43681 2/20 0.61
CHRNA7 P36544 6/20 0.59
APOBEC3A P31941 3/20 0.49
APOBEC3G Q9HC16 3/20 0.49
PABPC1 P11940 2/20 0.49
EIF4H Q15056 1/20 0.49
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 1/20 0.45
CHRM3 P20309 2/20 0.44
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM5 P08912 1/20 0.44
CHRM1 P11229 1/20 0.44
KDM4E B2RXH2 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
CYP2D6 P10635 1/20 0.41
CCR5 P51681 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL724930 1.00 CHRNB2 (0.61) CHRNB2CHRNA4CHRNA7APOBEC3AAPOBEC3G
Water SCHEMBL723735 0.98 CHRNB2 (0.59) CHRNB2CHRNA4CHRNA7APOBEC3AAPOBEC3G
Hydrochloric Acid SCHEMBL723900 0.98 CHRNB2 (0.59) CHRNB2CHRNA4CHRNA7APOBEC3AAPOBEC3G
Bromide SCHEMBL2450495 0.98 CHRNB2 (0.59) CHRNB2CHRNA4CHRNA7APOBEC3AAPOBEC3G
Iodide SCHEMBL11507837 0.98 CHRNB2 (0.65) CHRNB2CHRNA4CHRNA7APOBEC3AAPOBEC3G
Water SCHEMBL8939227 0.98 CHRNB2 (0.59) CHRNB2CHRNA4CHRNA7APOBEC3AAPOBEC3G
SCHEMBL3681307 0.98 CHRNA7 (0.60) CHRNB2CHRNA4CHRNA7APOBEC3AAPOBEC3G
Water SCHEMBL8939226 0.96 CHRNB2 (0.58) CHRNB2CHRNA4CHRNA7APOBEC3AAPOBEC3G
Hydrochloric Acid SCHEMBL2458828 0.96 CHRNA7 (0.58) CHRNB2CHRNA4CHRNA7APOBEC3AAPOBEC3G
Iodide SCHEMBL3691022 0.96 CHRNA7 (0.63) CHRNB2CHRNA4CHRNA7APOBEC3AAPOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1719768-B1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS ASAHI KASEI PHARMA CORP (JP) 2012-04-25 EP disclosed
US-20120015925-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2012-01-19 US disclosed
EP-1535913-B1 NOVEL QUATERNARY AMMONIUM COMPOUNDS ASAHI KASEI PHARMA CORP (JP) 2011-11-02 EP disclosed
US-7973030-B2 Benzothiazepine and benzothiepine compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-07-05 US disclosed
US-7803792-B2 Quaternary ammonium compounds ASAHI KASEI PHARMA CORPORATION (JP) 2010-09-28 US disclosed
US-7312208-B2 Quaternary ammonium compounds ASAHI KASEI PHARMA CORPORATION (JP) 2007-12-25 US disclosed
US-20070203115-A1 Novel quaternary ammonium compounds ASAHI KASEI PHARMA CORPORATION (JP) 2007-08-30 US disclosed
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds ASHAI KASEI PHARAMA CORPORATION (JP) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203115-A1 Novel quaternary ammonium compounds SLC10A2, SLC10A1, ABCB11 CHRNB2 2528/4885CHRNA4 3536/4885CHRNA7 3399/4885
US-20120015925-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS SLC10A1, SREBF1, SPTLC1 CHRNB2 4620/4885CHRNA4 3883/4885CHRNA7 3829/4885
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds SLC10A1, GOT1, CES1 CHRNB2 4564/4885CHRNA4 3309/4885CHRNA7 3152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.